Publication | Closed Access

A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer

OncologyMedicineColorectal CancerMetastatic Colorectal CancerPharmacotherapyCancer TreatmentOpen-label StudyPharmacologySteady-state Pharmacokinetics